Kolodziejczak A, Guerrini-Rousseau L, Planchon J, Ecker J, Selt F, Mynarek M
Neuro Oncol. 2023; 25(12):2273-2286.
PMID: 37379234
PMC: 10708940.
DOI: 10.1093/neuonc/noad114.
Penco-Campillo M, Molina C, Piris P, Soufi N, Carre M, Pagnuzzi-Boncompagni M
Cells. 2022; 11(23).
PMID: 36497191
PMC: 9738107.
DOI: 10.3390/cells11233933.
Goschzik T, Mynarek M, Doerner E, Schenk A, Spier I, Warmuth-Metz M
Acta Neuropathol. 2022; 144(6):1143-1156.
PMID: 36181537
PMC: 9637613.
DOI: 10.1007/s00401-022-02505-5.
Trejo-Solis C, Escamilla-Ramirez A, Jimenez-Farfan D, Castillo-Rodriguez R, Flores-Najera A, Cruz-Salgado A
Pharmaceuticals (Basel). 2021; 14(9).
PMID: 34577571
PMC: 8465904.
DOI: 10.3390/ph14090871.
Richardson S, Hill R, Kui C, Lindsey J, Grabovksa Y, Keeling C
Neuro Oncol. 2021; 24(1):153-165.
PMID: 34272868
PMC: 8730763.
DOI: 10.1093/neuonc/noab178.
Medulloblastoma Associated with Down Syndrome: From a Rare Event Leading to a Pathogenic Hypothesis.
Boni A, Ranalli M, Del Baldo G, Carta R, Lodi M, Agolini E
Diagnostics (Basel). 2021; 11(2).
PMID: 33562188
PMC: 7915142.
DOI: 10.3390/diagnostics11020254.
Medulloblastoma: molecular pathways and histopathological classification.
Borowska A, Jozwiak J
Arch Med Sci. 2016; 12(3):659-66.
PMID: 27279861
PMC: 4889700.
DOI: 10.5114/aoms.2016.59939.
Molecular Classification of Medulloblastoma.
Kijima N, Kanemura Y
Neurol Med Chir (Tokyo). 2016; 56(11):687-697.
PMID: 27238212
PMC: 5221779.
DOI: 10.2176/nmc.ra.2016-0016.
Radiation Sensitivity in a Preclinical Mouse Model of Medulloblastoma Relies on the Function of the Intrinsic Apoptotic Pathway.
Crowther A, Ocasio J, Fang F, Meidinger J, Wu J, Deal A
Cancer Res. 2016; 76(11):3211-23.
PMID: 27197166
PMC: 4891232.
DOI: 10.1158/0008-5472.CAN-15-0025.
p53 and Meduloblastoma.
Ramaswamy V, Nor C, Taylor M
Cold Spring Harb Perspect Med. 2015; 6(2):a026278.
PMID: 26684332
PMC: 4743072.
DOI: 10.1101/cshperspect.a026278.
WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma.
Zhukova N, Ramaswamy V, Remke M, Martin D, Castelo-Branco P, Zhang C
Acta Neuropathol Commun. 2014; 2:174.
PMID: 25539912
PMC: 4297452.
DOI: 10.1186/s40478-014-0174-y.
Anomalous altered expressions of downstream gene-targets in TP53-miRNA pathways in head and neck cancer.
Mitra S, Mukherjee N, Das S, Das P, Panda C, Chakrabarti J
Sci Rep. 2014; 4:6280.
PMID: 25186767
PMC: 5385823.
DOI: 10.1038/srep06280.
Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.
Zhukova N, Ramaswamy V, Remke M, Pfaff E, Shih D, Martin D
J Clin Oncol. 2013; 31(23):2927-35.
PMID: 23835706
PMC: 4878050.
DOI: 10.1200/JCO.2012.48.5052.
Medulloblastomics: the end of the beginning.
Northcott P, Jones D, Kool M, Robinson G, Gilbertson R, Cho Y
Nat Rev Cancer. 2012; 12(12):818-34.
PMID: 23175120
PMC: 3889646.
DOI: 10.1038/nrc3410.
Prognostic value of the TP53 Arg72Pro single-nucleotide polymorphism and susceptibility to medulloblastoma in a cohort of Brazilian patients.
Carvalho R, Pinto G, Yoshioka F, Lima P, Souza C, Guimaraes A
J Neurooncol. 2012; 110(1):49-57.
PMID: 22886512
DOI: 10.1007/s11060-012-0950-0.
Molecular subgroups of medulloblastoma.
Northcott P, Dubuc A, Pfister S, Taylor M
Expert Rev Neurother. 2012; 12(7):871-84.
PMID: 22853794
PMC: 4334443.
DOI: 10.1586/ern.12.66.
Diffuse intrinsic pontine tumors: a study of primitive neuroectodermal tumors versus the more common diffuse intrinsic pontine gliomas.
Sufit A, Donson A, Birks D, Knipstein J, Fenton L, Jedlicka P
J Neurosurg Pediatr. 2012; 10(2):81-8.
PMID: 22747092
PMC: 4690743.
DOI: 10.3171/2012.3.PEDS11316.
p53 expression predicts dismal outcome for medulloblastoma patients with metastatic disease.
Gessi M, von Bueren A, Rutkowski S, Pietsch T
J Neurooncol. 2011; 106(1):135-41.
PMID: 21796446
DOI: 10.1007/s11060-011-0648-8.
